RxDoctor Payments Data

Leland Sherlock

Optometrist · Mesa, AZNPI 1790758142

Payments from drug & device makers

$4,137in general payments, 2019–2025

Across 215 payments — averaging $19.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Aerie Pharmaceuticals, Inc.$939
  • AbbVie$770
  • Alcon$485
  • Kala Pharmaceuticals, Inc.$354
  • Alimera Sciences, Inc.$333
  • Bausch & Lomb Americas Inc.$281
  • plus $974 from 13 others

What the payments were for

  • Food & beverage$4,137100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,137 in reported general payments places this provider in the 90th percentile of 1,134 optometrist providers in Arizona.

See all optometrist providers in Arizona

Medicare billing

Part B allowed, 2024
$220,417
Medicare patients
1,167
Services billed
2,477

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine90$104,578
LumiganBimatoprost136$73,827
RocklatanNetarsudil Mesylat/Latanoprost40$33,740
XiidraLifitegrast19$27,730
EysuvisLoteprednol Etabonate28$16,678
Cyclosporine30$14,960
VyzultaLatanoprostene Bunod14$9,951
Latanoprost650$8,888
CombiganBrimonidine Tartrate/Timolol29$8,134
SimbrinzaBrinzolamide/Brimonidine Tart26$8,064
Prednisolone Acetate130$4,533
Alphagan PBrimonidine Tartrate14$4,029
Travoprost25$3,959
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol27$3,888
Brimonidine Tartrate125$3,378

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan, Alphagan P$770$190,568269 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$281$37,68133 claims
Aerie Pharmaceuticals, Inc.Rocklatan$939$33,74040 claims
Kala Pharmaceuticals, Inc.Eysuvis$354$16,67828 claims
AlconSimbrinza$485$8,06426 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,134 optometrist providers in Arizona.

Other optometrist in Mesa

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →